Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIGNITY Trial of durable glycemic control with imeglimin in type 2 diabetes mellitus
jRCTs031210623Active, not recruiting
- Sponsor
- Sumitomo Pharma
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial in type 2 diabetes mellitus (T2DM) comparing Imeglimin monotherapy, Metformin monotherapy and Vildagliptin monotherapy (3 arms). Started May 2022; status: active, not recruiting.
02
Drugs
imegliminmetforminvildagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCTs031210623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031210623.